Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-9966

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR ; volume:31 ; number:1 ; day:18 ; month:8 ; year:2012 ; pages:1-10 ; date:12.2012
Journal of experimental & clinical cancer research ; 31, Heft 1 (18.8.2012), 1-10, 12.2012

Creator: Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie

Contributor: SpringerLink (Online service)

DOI: 10.1186/1756-9966-31-65

URN: urn:nbn:de:101:1-2019070423064373408634

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie
SpringerLink (Online service)

Other Objects (12)

Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Related objects

Reset password